In a Move by the U.S. Department of Health and Human Services - Patient Limit on Access to Opioid Dependence Treatments to be Expanded

RALEIGH, N.C., Sept. 18, 2015 -- BioDelivery Sciences International, Inc. (BDSI) stated that the U.S. Department of Health and Human Services Secretary, Sylvia M. Burwell, announced important new steps to increase access to treatments for opioid dependence and prevention of opioid overdose.  A component of the planned changes includes a move to expand access to medication assisted treatment (MAT) by revising the regulations that limit the prescribing of buprenorphine to treat opioid dependence.

A recent report from HHS indicated that 2.5 million people in the U.S. currently need treatment for opioid dependence; however, fewer than 1 million are receiving it.  Under current regulations, physicians certified can prescribe buprenorphine treatment for opioid dependence for up to 30 patients initially and then after one year can request authorization to prescribe up to a maximum of 100 patients.  As a result, access to care is limited and physicians are often forced to turn away patients seeking care.  

"This is a major step forward in providing access to treatment for patients and their families who are dealing with opioid addiction," said Dr. Mark A. Sirgo, President and Chief Executive Officer of BioDelivery Sciences.  "We are very encouraged by the steps taken by the Department of Health and Human Services, including efforts to address what has been an ongoing barrier to treatment access. BioDelivery Sciences is fully committed to supporting efforts aimed at addressing the opioid epidemic in the U.S."

About BioDelivery Sciences International

BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company with a focus in the areas of pain management and addiction medicine.  BDSI is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA®) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of proven therapies aimed at addressing important unmet medical needs.

BDSI's development strategy focuses on utilization of the FDA's 505(b)(2) approval process. This regulatory pathway creates the potential for more timely and efficient approval of new formulations of previously approved therapeutics.

BDSI's particular area of focus is the development and commercialization of products in the areas of pain management and addiction. These are areas where BDSI believes its drug delivery technologies and products can best be applied to address critical unmet medical needs.  BDSI's marketed products and those in development address serious and debilitating conditions such as breakthrough cancer pain, chronic pain, painful diabetic neuropathy and opioid dependence.  BDSI's headquarters is located in Raleigh, North Carolina.  

 
 
Laura Radocaj
Dian Griesel International
212.825.3210
@dgicomm

 

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.